Celon Pharma SA (CLN)
Warsaw Stock Exchange · Poland · prices in PLN · close of 22 Oct 2026
Key indicators
| Last close | PLN 19.50 |
|---|---|
| 52-week range | 18.00 – 23.50 |
| Return, 1 month / 3 months | +0.0% / −5.3% |
| Return, 1 year / 3 years | −12.8% / +29.3% |
| Trend | Below its 200-day average |
| RSI (14) | 48 |
| Volatility (1 year) | 26.6% |
| Worst drawdown (1 year) | -20.5% |
| Average daily value traded | 0.36M PLN |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Celon Pharma is a Polish pharmaceutical company based near Warsaw that develops and manufactures medicines. It makes generic prescription drugs and also works on its own innovative treatments, including inhaled medicines delivered through its own inhaler technology and products for cancer and central nervous system conditions. The company carries out research and manufacturing at its own facilities and supplies patients and healthcare providers in Poland and in export markets.
On this site Celon Pharma SA appears as a stock on the Warsaw Stock Exchange (Poland), code CLN, with prices in Polish zloty (PLN). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Celon Pharma SA (CLN) trades on the Warsaw Stock Exchange in Poland. It last closed at PLN 19.50 on 22 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 198 of 580 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 12.8% and over the last three months it fell 5.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Warsaw Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 49 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -6.7% | ||
| From 52-week high | -17.0% | ||
| Momentum | 40 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -5.3% | ||
| 6-month return | -6.7% | ||
| 12-month return, skipping the last month | -12.8% | ||
| Stability (higher is calmer) | 83 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 26.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.5% | ||
| Liquidity | 78 · Strong | Trades actively. | |
| Average daily value traded | 0.36M PLN | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 3 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +3.5% |
|---|---|
| 1 month | +0.0% |
| 3 months | −5.3% |
| 6 months | −6.7% |
| 1 year | −12.8% |
| 3 years | +29.3% |
| 5 years | −45.4% |
Signals
| 50-day / 200-day average | 20.50 / 20.90 |
|---|---|
| Golden / death cross (60 days) | Death, 14 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.69 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 27 Jun 2024 | PLN 0.0800 |
| 29 Jun 2023 | PLN 0.0900 |
| 30 Jun 2022 | PLN 0.2900 |
| 14 Jul 2021 | PLN 0.0700 |
| 1 Jun 2020 | PLN 0.0800 |
| 29 Apr 2019 | PLN 0.2400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Warsaw Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.